Abstract
Background
Tumor markers are frequently used for screening and monitoring in oncology. We investigated the use of preoperative tumor marker (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA] 15-3) levels in estimating the prognosis of breast cancer patients.
Methods
We conducted a retrospective study in patients who underwent breast cancer surgery at National Cancer Center Hospital between 1975 and 1994 and whose serum CEA (n = 1663) and CA 15-3 (n = 1500) levels were measured prior to operation. When we excluded patients with stage IV disease from the study, the CEA level was within the normal range in 1470 patients, while 150 patients had an elevated CEA level. For CA 15-3, 1395 patients were within the normal range, while 70 patients exhibited an elevated level.
Results
The 5-year and 10-year survival rates for patients with normal CEA levels were 87% and 76%, respectively. However, the 5-year and 10-year survival rates for patients with elevated CEA levels were 76% and 65%, respectively. At both time points, patients with normal CEA levels had higher survival rates (P < 0.05). The 5-year and 10-year survival rates for the patients with normal CA 15-3 levels were 86% and 76%, respectively, while only 71% and 52% patients with elevated CA 15-3 levels survived at 5 and 10 years, respectively. These differences were also significant (P < 0.05). However, there were no significant differences in disease-free survival (DFS) according to CEA or CA 15-3 levels.
Conclusion
There was a positive correlation between CEA levels and CA 15-3 levels and patient prognosis. Thus, the levels of these tumor markers may help to determine prognosis in breast cancer patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Harris L, Frische H, Mennel R, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 25:5287–5312
Japanese Breast Cancer Society (2004) General rules for clinical and pathological recording of breast cancer, 15th edn (in Japanese). Kanehara, Tokyo
Molina R, Filella X, Alicarte J, et al. (2003) Prospective evaluation of CEA and CA 15-3 in patients with locoregional breast cancer. Anticancer Res 23:1035–1042
Hayes DF, Zurawski VR, Kufe DW (1986) Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542–1546
Molina R, Filella X, Mengual P, et al. (1990) MCA in patients with breast cancer: correlation with CEA and CA 15-3. Int J Biol Markers 5:14–21
Molina R, Ballesta AM (1991) Evaluation of several tumor markers (MCA, CA 15-3, BCM, and CA549) in tissue and serum of patients with breast cancer. In: Ceriani RL (ed) Breast epithelial antigens. Molecular biology to clinical applications. Plenum, New York, pp 161–163
Dnistrian AM, Schwartz MK, Greenberg EJ, et al. (1991) Evaluation of CAM26, CAM29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol 12:1282–1290
Molina R, Fiella X, Zanon G, et al. (2003) Prospective evaluation of tumor markers (c-erb B-2 oncoprotein, CEA, CA 15-3) in patients with locoregional breast cancer: Anticancer Res 23: 1043–1050
Guadagni F, Ferroni P, Carlini S, et al. (2001) A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7:2357–2362
Sutterlin M, Bussen S, Trott S, et al. (1999) Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer. Anticancer Res 19:2567–2570
Gion M, Mione R, Leon AE, et al. (2001) CA27-29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer. 37:355–363
Nicolini A, Carpi A, Michelassi C, et al. (2003) Tumour marker guided salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 57:452–459
The GIVIO investigators (1994) Impact of follow up testing on survival and health-related quality of life in breast cancer patients. JAMA 271:1587–1592
Turco M, Cariddi D, Pacini S, et al. (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA 271:1593–1597
Soletormos G, Nielsen D, Schioler V, et al. (2004) Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 40:481–486
Lumachi F, Brandes AA, Ermani M, et al. (2000) Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 20:4751–4756
Lumachi F, Brandes AA, Boccagni P, et al. (1999) Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 19:4485–4490
Molina R, Jo J, Filella X, et al. (1999) C-erb b-2 CEA and CA 15-3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 19:2551–2556
Sutterlin M, Bussen S, Trott S, et al. (1999) Predictive value of CEA and CA 15-3 in the follow-up of invasive breast cancer. Anticancer Res 19:2526–2570
Lauro S, Trasatti L, Bordin F, et al. (1999) Comparison of CEA, MCA, CA 15-3 and CA27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 19: 3511–3516
Pectasides D, Pavlidis N, Gogou L, et al. (1996) Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 19:459–464
Jezersek B, Cervek J, Rudolf Z, et al. (1996) Clinical evaluation of potential usefulness of CEA, CA 15-3 and MCA in follow-up of breast cancer patients. Cancer Lett 110:137–144
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Uehara, M., Kinoshita, T., Hojo, T. et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 13, 447–451 (2008). https://doi.org/10.1007/s10147-008-0773-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-008-0773-3